NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
| 1.34 | |
| 1.36 | |
| - | |
| 1.3845 | |
| 1.32 | |
| 1.25-21 | |
| 1 892 K | |
| 1 371 K | |
| 0 | |
| -2.4608 | |
| 1.937 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
A JDRF funded grant is being used to explore the combination of NexImmune’s antigen specific nanoparticles and an anti-CD3 mAb for prevention and treatment of type 1 diabetes GAITHERSBURG, Md., Oct...
GAITHERSBURG, Md., Oct. 19, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by direct...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
